{
    "clinical_study": {
        "@rank": "45201", 
        "arm_group": [
            {
                "arm_group_label": "Group 1: DE-117 ophthalmic solution", 
                "arm_group_type": "Experimental", 
                "description": "One drop DE-117 Low Dose in each eye daily for 28 days"
            }, 
            {
                "arm_group_label": "Group 2: DE-117 ophthalmic solution", 
                "arm_group_type": "Experimental", 
                "description": "One drop DE-117 Low Middle Dose in each eye daily for 28 days"
            }, 
            {
                "arm_group_label": "Group 3: DE-117 ophthalmic solution", 
                "arm_group_type": "Experimental", 
                "description": "One drop DE-117 High Middle Dose in each eye daily for 28 days"
            }, 
            {
                "arm_group_label": "Group 4: DE-117 ophthalmic solution", 
                "arm_group_type": "Experimental", 
                "description": "One drop DE-117 High Dose in each eye daily for 28 days"
            }, 
            {
                "arm_group_label": "latanoprost ophthalmic solution", 
                "arm_group_type": "Active Comparator", 
                "description": "One drop latanoprost 0.005% in each eye daily for 28 days"
            }, 
            {
                "arm_group_label": "placebo (vehicle of DE-117) ophthalmic solution", 
                "arm_group_type": "Placebo Comparator", 
                "description": "One drop DE-117 vehicle in each eye once daily for 28 days"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the safety and efficacy of four concentrations\n      of DE-117 ophthalmic solution."
        }, 
        "brief_title": "Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "condition": "Open-angle Glaucoma or Ocular Hypertension", 
        "condition_browse": {
            "mesh_term": [
                "Glaucoma", 
                "Glaucoma, Open-Angle", 
                "Hypertension", 
                "Ocular Hypertension"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a 28-day randomized, observer-masked, placebo-and active-controlled, parallel-group,\n      multi-center, study investigating the safety and efficacy of four concentrations of DE-117\n      ophthalmic solution when compared to latanoprost (0.005% latanoprost) and placebo (vehicle\n      of DE-117) in subjects with primary open-angle glaucoma or ocular hypertension."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Main Inclusion Criteria:\n\n          -  Current diagnosis of primary open-angle glaucoma or ocular hypertension in both eyes\n\n          -  Qualifying intraocular pressure in at least one eye at Baseline\n\n          -  Qualifying corrected ETDRS visual acuity in each eye\n\n          -  Qualifying central cornea thickness in each eye\n\n        Main Exclusion Criteria:\n\n          -  Closed/barely open anterior chamber angle or a history of acute angle closure in\n             either eye\n\n          -  Diagnosis of primary open-angle glaucoma or ocular hypertension due to etiology known\n             to be non-responsive to conventional drug therapy\n\n          -  Evidence of advanced glaucoma, visual field defect or progressive visual field loss\n             that that do not meet the study criteria\n\n          -  History of ocular surgery specifically intended to lower IOP\n\n          -  History of any ocular or systemic abnormality or condition that may put the subject\n             at significant risk, may confound study results, or may interfere significantly with\n             the subject's participation in the study\n\n          -  Intended or current use of any ocular medications other than study medications during\n             the study\n\n          -  Use of contact lenses within one week prior to Baseline (Day 1) until end of\n             treatment\n\n          -  Known allergy or sensitivity to any components of the study medications\n\n          -  Use of steroids (systemic) within 30 days prior to Visit 1 (Screening)\n\n          -  Anticipate the need to initiate or modify an existing chronic therapy that could\n             substantially affect IOP or the study outcomes during the study period\n\n          -  Females who are pregnant, nursing or planning a pregnancy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "91", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01868126", 
            "org_study_id": "33-002"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Group 1: DE-117 ophthalmic solution", 
                    "Group 2: DE-117 ophthalmic solution", 
                    "Group 3: DE-117 ophthalmic solution", 
                    "Group 4: DE-117 ophthalmic solution"
                ], 
                "intervention_name": "DE-117 ophthalmic solution", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "latanoprost ophthalmic solution", 
                "intervention_name": "latanoprost ophthalmic solution", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "placebo (vehicle of DE-117) ophthalmic solution", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Latanoprost"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Santen", 
            "Eye", 
            "Glaucoma", 
            "Ocular hypertension"
        ], 
        "lastchanged_date": "January 6, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Newport Beach", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92663"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Morrow", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30260"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kansas City", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "64133"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14618"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44115"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Austin", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78731"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78240"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "6", 
        "official_title": "A Phase II, Randomized, Observer-masked, Placebo-and Active-controlled, Parallel-group, Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost and Placebo in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Intraocular pressure (mmHg) measurements will be collected at each visit using Goldmann applanation tonometry", 
            "measure": "Intraocular pressure (mmHg)", 
            "safety_issue": "No", 
            "time_frame": "Day 1, Day 8, Day 15 and Day 29"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01868126"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Adverse events will be assessed at each visit to evaluate safety", 
                "measure": "Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1, Day 8, Day 15 and Day 29"
            }, 
            {
                "description": "Ocular symptoms and ocular signs will be collected at each visit using slit lamp biomicroscopy, dilated ophthalmoscopy, gonioscopy, automated perimetry visual field testing, corrected visual acuity and pachymetry", 
                "measure": "Ocular signs and symptoms", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1, Day 8, Day 15 and Day 29"
            }
        ], 
        "source": "Santen Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Santen Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}